Introduction {#Sec1}
============

Serum 25(OH)D~3~ level is the accepted indicator of vitamin D~3~ sufficiency in humans. Since dietary sources of vitamin D~3~ are limited, the major cause of human vitamin D~3~ insufficiency (defined as serum 25(OH)D~3~ \< 32 ng/mL) is inadequate exposure to the sun \[[@CR1], [@CR2]\]. Several factors including living at higher latitudes, cultural practices limiting skin exposure to sunlight, advanced age, obesity, and dark skin pigmentation are associated with low serum 25(OH)D~3~ levels \[[@CR3]--[@CR5]\]. We have reported that recent cancer chemotherapy may be a predisposing factor for vitamin D~3~ deficiency in CRC patients \[[@CR6]\].

The clinical significance of vitamin D insufficiency in patients with established colorectal cancer, especially those with metastatic disease, is unclear. However, the association between vitamin D~3~ insufficiency and an increased risk of developing colorectal cancer is supported by several case--control studies \[[@CR7], [@CR8]\]. In a Norwegian study, higher colorectal cancer mortality was observed when the diagnosis of colon cancer was made during winter or spring (lower 25(OH)D~3~) compared to summer and autumn (higher 25(OH)D~3~) \[[@CR9]\]. Furthermore, the Nurse's Health Study (NHS) and Health Professionals follow-up study showed that the lowest risk of death (adjusted for other variables) from CRC disease was seen in patients in the highest quartile of serum 25(OH)D~3~ levels \[[@CR10]\].

Polymorphisms in several vitamin D genes (*CYP2R1*, *CYP27A1*, *CYP27B1*, *CYP24A1*, *VDBP* and *VDR*) have been associated several human diseases, including CRC \[[@CR11]\]. The proteins encoded by these genes include CYP2R1 and CYP27A1 which convert vitamin D to 25(OH)D~3~. 25(OH)D~3~ is then converted by CYP27B1 to 1,25(OH)~2~D~3~, the biologically most active form of vitamin D~3~. CYP24A1 converts 25(OH)D~3~ and 1,25(OH)~2~D~3~ to 24, 25(OH)~2~D~3~ and 1, 24, 25(OH)~2~D~3~, respectively, which are less active. Vitamin D binding protein (VDBP), encoded by *GC* (group-specific component), is the transporter of vitamin D~3~ metabolites in circulation while VDR, a nuclear hormone receptor, mediates the action of vitamin D~3~ by transcriptionally controlling the expression of hormone sensitive genes. Studies show significant association between single nucleotide polymorphisms (SNP) in the *GC* (rs2282679), *DHCR7* (rs12785878), and *CYP2R1* (rs10741657) genes and serum 25(OH)D~3~ levels \[[@CR12], [@CR13]\]. There are reported associations between 25(OH)D~3~ levels and SNPs in *GC* (rs4588 and rs7041), *VDR* (rs10735810) and *CYP27B1* (rs10877012) genes \[[@CR14], [@CR15]\]. The AA genotype of *VDR* rs1544410 has been associated with higher serum 1,25(OH)~2~D~3~ levels compared to the GG genotype \[[@CR16]\]. Reports on the effect of D~3~ supplementation on the associations between polymorphisms in the vitamin D~3~ pathway genes and serum 25(OH)D~3~, 24,25(OH)~2~D~3~ and 1,25(OH)~2~D~3~levels are few. A suboptimal response to D~3~ supplementation was associated with *GC* rs4588 SNP in healthy adults \[[@CR17]\]. Comprehensive studies to identify SNPs in the vitamin D~3~ metabolizing and signaling pathway genes that are associated with response to D~3~ supplementation will provide insight into factors influencing vitamin D health and information on the planning of prospective cancer chemoprevention and therapeutic clinical trials.

In this study, we measured serum vitamin D metabolite levels (25(OH)D~3~, 24,25(OH)~2~D~3,~ 1,25(OH)~2~D~3~) together with vitamin D binding protein (VDBP ) levels in 313 CRC patient samples and correlated these measures with SNPs in the major vitamin D~3~ metabolizing and signaling pathway genes at baseline and with vitamin D sufficiency. We also tested for associations between these SNPs and changes in the serum vitamin D~3~ metabolites levels in a subset of CRC patients receiving a fixed dose of 2,000 IU of oral cholecalciferol daily for 6 months.

Materials and Methods {#Sec2}
=====================

Research Blood Sample Collections and Storage {#Sec3}
---------------------------------------------

Archived blood samples of 263 CRC patients were obtained from Roswell Park Cancer Institute (RPCI) Data Bank and BioRepository. Blood samples were also collected prospectively from RPCI CRC patients enrolled in a study of fixed oral dose of 2000 IU of cholecalciferol (D~3~) once daily for 6 months. Eligibility criteria, baseline and follow-up clinical evaluation of the patients enrolled in the D~3~ supplementation protocol has been published \[[@CR18]\]. Protocols for these studies were both approved by the RPCI Institutional Review Board (IRB) prior to starting these studies.

Serum samples for vitamin D~3~ metabolite and PTH level measurements were collected before treatment and on days 14, 30, 60, 90, and 180 of D~3~ supplementation and stored at −80 °C until assayed. VDBP was measured in samples collected at baseline and on day 90 only. Baseline blood samples collected in EDTA tubes and stored at −80 °C was used for DNA isolation. Serum samples for PTH assay were stored at −80 °C and were assayed within 12 months of samples collection. PTH levels in archived serum samples were not measured.

Analytical Assays {#Sec4}
-----------------

### Serum 25(OH)D~3~, 24,25(OH)~2~D~3~, and 1,25(OH)~2~D~3~ Assays {#Sec5}

A high-performance liquid chromatographic assay with tandem mass spectrometric detection (LC/MS/MS) was used to simultaneously measure 24,25(OH)~2~D~3~ and 25(OH)D~3~ in 0.25 mL of human serum sample. Stable-isotope labeled 25-Hydroxyvitamin D~3~-(26,26,27,27,27-*d*6) was the internal standard \[[@CR19], [@CR20]\]. Sample preparation for LC/MS/MS analysis included liquid--liquid extraction using methanol and chloroform (1:3 *v*/*v*). The dried organic layer containing 24,25(OH)~2~D~3~ and 25(OH)D~3~ was reconstituted in 60 μL of methanol (MeOH)/water (60/40 %) and 25 μL volumes were injected and separated on reverse phase dC-18 column (Waters Corp) using MeOH/water gradient (0 min 80 % MeOH, 3 min 99 % MeOH, 10 min 99 % MeOH,10.1 min 80 % MeOH, 15 min 80 % MeOH at flow rate of 220 μL/min). TSQ Quantum ULTRA mass spectrometer with positive atmospheric pressure chemical ionization (APCI) source was used to monitor 24,25(OH)~2~D~3~, 25(OH)D~3~ and the internal standard at transitions of *m*/*z* 399 \> 127, 383 \> 365 and 389 \> 371 respectively. The assay lower limit of detection were 0.25 ng/mL for both 24,25(OH)~2~D~3~ and 25(OH)D~3~. Serum 25(OH)D~3~ levels measured by our LC/MS/MS method were 10--17 % higher than the values obtained using DiaSorin 25-hydroxyvitamin D RIA kits. Serum 1,25(OH)~2~D~3~ levels were measured using DiaSorin RIA kits as previously described \[[@CR21]\].

### Plasma PTH and VDBP Assays {#Sec6}

Serum PTH levels were measured using biologically intact hPTH 1--84 immunoradiometric Kits from DiaSorin (Stilwell, MN). Quantitative determination of total serum vitamin D binding proteins (VDBP) was performed using K2314 VDBP ELISA kits from ALPCO immunoassays (Salem, NH). Both assays were performed according to the instructions supplied with kits.

### 24-Hydroxylase Activity Assay {#Sec7}

PBMC 24-OHase activity was assayed as previously described \[[@CR22], [@CR23]\]. The assay consisted of 2 × 10^6^ PBMC (as the 24-OHase enzyme source), and 0.5 μCi (110,000 dpm) \[^3^H\]-25(OH)D~3~ as the substrate; total assay volume was 0.5 ml of buffer (0.19 M sucrose, 25 mM sodium succinate, 2 mM MgCl~2,~ 1 mM EDTA and 20 mM HEPES), pH 7.4. The reaction was initiated by the addition of substrate followed by 30 min incubation at 37 °C. \[^3^H\]-25(OH)D~3~ oxidative metabolites were extracted by liquid--liquid partition, separated by HPLC and measured by liquid scintillation counting of collected HPLC fractions. Radioactivity in the fractions containing all 24-oxidative metabolites of 25(OH)D~3~ were pooled and 24-OHase activity, normalized for variations in extraction efficiency, was calculated using the radioactivity ratio of pooled 24-oxidative metabolites/total radioactivity recovered and expressed as femtomoles per hour per mg of protein.

### Genotyping Assays {#Sec8}

Genomic DNA was isolated from whole blood samples using Flexi Gene DNA kits (Qiagen Inc, Valencio, CA). The quality and quantity of DNA isolated was determined using both Nanodrop (Thermo Scientific, Waltham, MA) and PicoGreen (Molecular Probes Inc., Eugene, OR) methods.

TagSNPs in *CYP2R1*, *CYP27A1*, *CYP27B1*, *CYP24A1*, *VDR* and *GC* genes were selected from databases (NCBI; HapMap) and from *CYP24A1* re-sequenced data generated in our laboratory from Caucasian DNA samples from the Coreil Cell Repository (unpublished). Briefly, SNP genotype datasets for Caucasians were loaded into the Haploview program (version 4.0) (Broad Institute, MIT and Harvard, Cambridge, MA, USA) and polymorphisms with frequencies greater than 5 % were selected for haplotype analysis at an *r*^2^ threshold of 0.8. Haplotypes close to or greater than 2 % were organized into single blocks from which haplotype tagSNPs were derived. The tagger software was also used to generate tagSNPs. Other websites used for tagSNPs selection included NIEHS (<http://snpinfo.niehs.nih.gov/snptag.htm>) and GVS (<http://gvs.gs.washington.edu/GVS/>). A total of 80 tagSNPs were genotyped using the Sequenom MassArray platform (Sequenon, San Diego, CA) in accordance with the manufacturer's instructions (<http://www.sequenom.com/seq-genotyping>). Controls were included to ensure genotyping accuracy in addition to genotyping approximately 10 % of the samples in duplicates.

Data Analysis {#Sec9}
-------------

Patients with baseline serum 25(OH)D~3~ levels \<20 ng/mL, 20--31.9 ng/mL and ≥32 ng/mL were considered to be vitamin D~3~ deficient, insufficient and sufficient, respectively. Free index (a measure of non-protein bound) 25(OH)D~3~, 24,25 (OH)~2~D~3~ and 1,25(OH)~2~D~3~ were calculated as a molar ratio of each vitamin D~3~ metabolite/VDBP. Frequencies and relative frequencies were computed for categorical variables and numeric variables were summarized using mean, standard deviation, standard error of mean, median and range as appropriate. Fisher's exact test was used to study the association between categorical variables and the Wilcoxon rank sum test was used to compare the groups' numeric variables.

The generalized linear models with corresponding link function and distribution of different response variables were used to investigate the association between study variables and a set of variables for multivariate analysis. *P* \< 0.05 nominal significance level was used in all testing. All statistical analyses were done using SAS (version 9.1).

Association analysis of serum vitamin D~3~ metabolite concentrations with SNPs were performed using generalized linear models. Logistic regression models were used to measure SNP association analyses with sufficiency status (insufficient/deficient vs. sufficient). For the D~3~ supplementation population, vitamin D~3~ metabolite levels were log transformed and genotypes were coded as 0, 1, and 2 for homozygous major, heterozygous and homozygous minor genotypes, respectively. Due to small sample size of D~3~ supplementation group and rarity of minor genotypes, the minor and heterozygous genotypes were pooled and compared to major genotype (reference group) for all SNPS. Models were adjusted for age, sex, BMI, tumor stage, chemotherapy status and plasma VDBP levels. The β-coefficients from the linear models represent the quantitative change in plasma measures with the addition of the minor allele. The β coefficients from the logistic regression models reflect the increase in odds of deficiency (or sufficiency) with each additional copy of the variant allele.

Results {#Sec10}
=======

Patient Characteristics, Baseline Serum Vitamin D~3~ Metabolite and VDBP Levels {#Sec11}
-------------------------------------------------------------------------------

Characteristics, including self-reported racial background, of all 313 CRC patients, stratified into three vitamin status categories (deficient, insufficient, and sufficient, based on baseline serum 25(OH)D~3~ levels), are shown in Table [1](#Tab1){ref-type="table"}; 69.1 % of the vitamin D~3~ sufficient patients had blood samples collected in summer/fall compared to 52.2 % and 39.8 % for the insufficient and deficient patients, respectively. Neither BMI nor other patient demographic characteristics (gender, age, race, and tumor stage) showed significant association with vitamin D~3~ status. Serum 24,25(OH)~2~D~3~ levels were significantly associated with baseline serum 25(OH)D~3~ levels (*p* \< 0.0001), whereas serum 1,25(OH)~2~D~3~ and VDBP levels were not.Table 1Demographic and serum vitamin D~3~ variables in CRC patients stratified by baseline serum vitamin D~3~ statusCharacteristics/variablesBaseline vitamin D~3~ status\**p* valueDeficient (*N* = 88)Insufficient (*N* = 115)Sufficient (*N* = 110)Age, years \<404490.4440--4913241250--5926263260--69293734≥70152523GenderF44 (50 %)48 (41.7 %)55 (50 %)0.37M44 (50 %)67 (58.3 %)55 (50 %)RaceWhite76 (86.4 %)101 (87.8 %)100 (90.9 %)0.52Black8 (9.1 %)12 (10.4 %)6 (5.5 %)Others4 (4.5 %)2 (1.7 %)4 (3.6 %)Tumor stageEarly (I/II)8 (9.1 %)18 (15.8 %)16 (14.7 %)0.35Advanced (III/IV)80 (90.9 %)96 (84.2 %)93 (85.3 %)Sample collection seasonSummer--Fall35 (39.8 %)60 (52.2 %)76 (69.1 %)0.004Winter--Spring53 (60.2 %)55 (47.8 %)34 (30.9 %)BMI (kg/m^2^)\<2527 (30.7 %)23 (21.3 %)34 (33.0 %)0.06525--3025 (28.4 %)43 (39.8 %)42 (40.8 %)\>3036 (40.9 %)42 (38.9 %)27 (26.2 %)Vitamin D binding protein (VDBP) (μg/mL)354.1 ± 77.6357.8 ± 75.0387.3 ± 102.40.079D~3~ metabolites25(OH)D~3~ (ng/mL)14.4 ± 4.025.7 ± 3.438.8 ± 5.9Inference24,25(OH)~2~D~3~(ng/ml)0.4 ± 0.31.0 ± 0.72.2 ± 2.1\<0.00011,25 (OH)~2~D~3~ (pg/mL)53.0 ± 16.253.5.4 ± 15.154.2 ± 15.40.46For numerical variables statistics represented as mean ± SDFor categorical variables statistics represented as frequency (% relative frequency)\*Definitions of vitamin D~3~ status categories are based on serum 25(OH)D~3~ levels\<20ng/mL = deficient, 20--31.9 ng/mL = insufficient and ≥32ng/mL = sufficient

Effect of D~3~ Supplementation on Serum Vitamin D~3~ Metabolites, PTH, VDBP Levels and PBMC 24-OHase Activity {#Sec12}
-------------------------------------------------------------------------------------------------------------

Time course of the changes in serum 25(OH)D~3,~ 24,25(OH)~2~D~3~, 1,25(OH)~2~D~3~, PTH and VDBP levels and PBMC 24-OHase activity during D~3~ supplementation are shown in Fig. [1](#Fig1){ref-type="fig"}. The increase in 25(OH)~2~D~3~ attained equilibrium levels by day 90; the largest percentage increase in 25(OH)D~3~ levels was in the vitamin D~3~ deficient category (Fig. [1a](#Fig1){ref-type="fig"}). Similar increases in 24,25(OH)~2~D~3~ levels were observed (Fig. [1b](#Fig1){ref-type="fig"}). The 1,25(OH)~2~D~3~ levels also increased but remained within the physiologic range of 20--100 pg/mL (Fig. [1c](#Fig1){ref-type="fig"}). Serum 25(OH)D~3~ and 24,25(OH)~2~D~3~ levels at baseline and during D~3~ supplementation were linearly correlated (Fig. [1d](#Fig1){ref-type="fig"}). The correlation between 25(OH)D~3~ and 1,25(OH)~2~D~3~, and between 24,25(OH)~2~D~3~ and 1,25(OH)~2~D~3~ serum levels are shown in Fig. [1e and f](#Fig1){ref-type="fig"}, respectively.Fig. 1Time course of the changes in serum 25(OH)D~3~ (panel **a**), 24,25(OH)~2~D~3~ (panel **b**), and 1,25(OH)~2~D~3~ (panel **c**) levels in vitamin D~3~ deficient (*filled circle*), insufficient (*open circle*), and sufficient (*filled square*) CRC patients receiving 2000IU of oral cholecalciferol daily. Vitamin D~3~ status stratification based on baseline serum 25(OH)D~3~ levels: deficient \< 20 ng/mL (*N* = 9), insufficient 20 to 31.9 ng/mL (*N* = 24) and sufficient ≥ 32ng/mL (*N* = 17). Panels **d**, **e**, and **f** show plots (and correlation coefficients) of serum 25(OH)D~3~ versus 24,25(OH)~2~D~3~, 25(OH)D~3~ versus 1,25(OH)D~3~, and 24,25(OH)~2~D~3~ versus 1,25(OH)D~3~ levels at baseline and during D~3~ supplementation. Caption in panel **a**, also refers to panels **b** and **c**

A decrease in serum PTH levels was observed within 30 days of starting D~3~ supplementation and no further decrease in PTH levels was observed from day 60 onwards (Fig. [2a](#Fig2){ref-type="fig"}). No significant changes in PBMC 24-OHase activity and serum VDBP levels were observed during D~3~ supplementation (Fig. [2b and c](#Fig2){ref-type="fig"}). Baseline and day 90 serum VDBP levels for all three vitamin D~3~ status categories were within the normal range (200--550 μg/mL). D~3~ supplementation increased the free indices of serum 25(OH)D~3~ and 24,25(OH)~2~D~3~ (Fig. [2d and e](#Fig2){ref-type="fig"}); 1,25(OH)~2~D~3~ free index did not change (Fig. [2f](#Fig2){ref-type="fig"}).Fig. 2Time course of the change in serum PTH levels (panel **a**) and PBMC 24-hydroxylase activity (panel **b**) in vitamin D~3~ deficiency (*filled circle*, *N* = 9), insufficient (*open circle*, *N* = 24), and sufficient (*filled square*, *N* = 17) CRC patients receiving 2,000 IU of oral cholecalciferol daily; panel **c** shows the baseline and day 90 serum VDBP levels. Net effects of the cholecalciferol supplementation mediated changes in plasma vitamin D~3~ metabolite and VDBP levels were evaluated by calculating free index of 25(OH)D~3~ (panel **d**), 24,25(OH)~2~D~3~ (panel **e**) and 1,25(OH)~2~D~3~ (panel **f**) at baseline and on day 90 of the D~3~ supplementation. Free index = molar ratio of vitamin D~3~ metabolite/VDBP

In summary, the significant consequences of D~3~ supplementation were the decrease in serum PTH levels by day 30, and increase in 25(OH)D~3~ levels on days 30 and 90; the changes in serum of 24,24(OH)~2~D~3~, 1,25(OH)~2~D~3~ and VDBP levels and PBMC 24-OHase were not significant at any of the time points analyzed (Table [2](#Tab2){ref-type="table"}).Table 2Changes in vitamin D~3~ metabolites and other vitamin D~3~ related variables measured during D~3~ supplementation in 50 CRC patients categorized by vitamin D~3~ statusTime (days)Changes in serum D~3~ variables from baselineVitamin D~3~ status*p* valueDeficient (*N* = 9)Insufficient (*N* = 24)Sufficient (*N* = 17)30Δ25(OH)D~3~20.6 ± 5.915.5 ± 7.811.0 ± 9.60.009Δ24,25(OH)~2~D~3~0.8 ± 0.60.6 ± 0.60.7 ± 1.20.80Δ1,25(OH)~2~D~3~7.5 ± 20.56.5 ± 15.14.4 ± 18.70.9ΔPTH−35.5 ± 18.2−15.4 ± 25.0−16.3 ± 19.90.04ΔPBMC CYP24A1 activity3.5 ± 10.12.0 ± 6.0−0.3 ± 8.40.7090Δ25(OH)D~3~34.5 ± 11.126.3 ± 11.613.8 ± 11.30.0007Δ24,25(OH)~2~D~3~1.5 ± 1.01.7 ± 1.01.3 ± 1.70.30Δ1,25(OH)~2~D~3~23.7 ± 20.99.4 ± 20.51.0 ± 23.10.10ΔPTH−32.0 ± 14.0−21.6 ± 29.4−15.1 ± 23.40.20ΔVDBP44.4 ± 71.2−3.4 ± 61.8−69.3 ± 166.10.09180Δ25(OH)D~3~32.5 ± 14.627.5 ± 12.021.7 ± 15.40.20Δ24,25(OH)~2~D~3~2.0 ± 1.32.3 ± 1.22.1 ± 2.00.60Δ1,25(OH)~2~D~3~31.1 ± 19.629.3 ± 27.412.0 ± 27.00.10ΔPTH−30.3 ± 23.4−24.1 ± 24.4−13.3 ± 21.70.20Statistics represent mean ± SD. Tests for equality for all the variables between baseline 25(OH)D~3~ groups at baseline, day 30, 90 and 180 done by Chi-square tests

Vitamin D SNPs and Serum Vitamin D~3~ Metabolite Levels and Risk of Vitamin D~3~ Insufficiency {#Sec13}
----------------------------------------------------------------------------------------------

Associations between the tag SNPs from the 6 genes (*VDR*, *GC*, *CYP2R1*, *CYP27A1*, *CYP27B1*, and *CYP24A1*) with baseline serum levels of 25(OH)D~3~, 24,25(OH)~2~D~3~, and 1,25(OH)~2~D~3~ were evaluated in the 313 CRC patients. At *p* \< 0.05, two *GC* SNPs (rs4588 and rs2282679, in linkage disequilibrium \[LD\] with each other, *r*^2^ = 0.98), two *CYP24A1* SNPs (rs2762934 and rs2762939) and one *VDR* SNP (rs11168267) were associated with low baseline levels of at least one serum vitamin D~3~ metabolite; SNPs associated with high baseline levels of at least one serum vitamin D~3~ metabolite were *GC* rs222016, *CYP24A1* rs111675277 and *VDR* rs11574077 (Table [3](#Tab3){ref-type="table"}). After multiple testing, only *GC* rs4588 remained significantly associated with low baseline serum 1,25(OH)~2~D~3~ levels.Table 3Associations between SNPs in the vitamin D~3~ pathway genes with serum 25(OH)D~3~, 24,25(OH)~2~D~3~ and 1,25(OH)~2~D~3~ levels at baseline and after 90-days of D~3~ supplementationD~3~ metabolitesGeneSNP IDFunctionBaseline (*N* = 313)After D~3~ supplementation (*N* = 50)^a^*βp* value^b^*βp* value^b^25(OH)D~3~*GC* (*VDBP*)rs4588Exon/Missense−2.430.017−0.190.0009rs2282679Intron−2.490.015−0.190.0008rs222016Intron2.240.035Not significant*CYP2R1*rs10500804IntronNot significant−0.130.04rs12794714Exon/Synonymous−0.130.04rs7129781Intron0.230.04*CYP24A1*rs111675277Intron5.150.028Not significant*VDR*rs11168267Intron−3.590.03024,25(OH)~2~D~3~*CYP2R1*rs7129781IntronNot significant0.530.02*CYP24A1*rs6022999Intron−0.320.02*VDR*rs11574077Intron0.710.023Not significant1,25(OH)~2~D~3~*GC* (*VDBP*)rs4588Exon/Missense−4.860.0008^c^−0.280.01rs2282679Intron−4.690.0012−0.270.02rs222016Intron3.400.025Not significant*CYP24A1*rs2762934mRNA-untranslated−4.010.010rs2762939Intron−3.720.007*VDR*rs2525044IntronNot significant−0.340.007rs11574077Intron0.590.01rs739837mRNA-untranslated−0.420.002rs7975232Intron−0.430.001Only significant association (*p* \< 0.05) between SNPs and either baseline or day-90 plasma vitamin D~3~ variables are shown. The only baseline and day-90 overlapping associations were between *GC* (rs4855 and rs2282679) with both 25(OH)D~3~ and 1,25(OH)~2~D~3~. SNPs in linkage disequilibrium \[LD\]: rs4855/rs2282679 (r^2^ = 0.98), rs10500804/rs12794714 (r^2^ = 1.0) and rs7975232/rs739837 (*r*^2^ = 0.9). *CYP2R1* rs7129781 was associated with high 25(OH)D~3~ and 24,25(OH)~2~D~3~ levels after D~3~ supplementation while *VDR* rs11574077 was associated with high 1,25(OH)~2~D~3~ levels^a^Most frequent genotype was used as reference and compared with pooled heterozygous and rare genotypes because of small sample size^b^Raw *p* values (not corrected for multiple testing)^c^The only significant association after multiple testing

The *GC* rs4588 and rs2282679 SNPs were associated with less increase in serum 25(OH)D~3~ and 1,25(OH)~2~D~3~ levels after 90 days of D~3~ supplementation in 50 patients (Table [3](#Tab3){ref-type="table"}). Six other SNPs, rs10500804 and rs12794714 (*CYP2R1*), rs6022999 (*CYP24A1*) and rs2525044, rs739837, rs7975232 (*VDR*) were also associated with low levels of at least one vitamin D metabolite after supplementation (Table [3](#Tab3){ref-type="table"}). Only two SNPs were associated with higher serum vitamin D~3~ metabolite levels after supplementation (Table [3](#Tab3){ref-type="table"}).

The risk of vitamin D insufficiency in association with tagSNPs was evaluated in the 313 CRC patients stratified into 2 groups: vitamin D~3~ sufficient (reference, baseline serum 25(OH)D~3~ ≥ 32ng/ml) and vitamin D~3~ insufficient (baseline serum 25(OH)D~3~ \< 32ng/mL). *GC* rs4588 and rs2282679 were associated with increased odds of vitamin D~3~ insufficiency while *GC* rs222014 and *CYP24A1* rs4809958 and rs6013905 in LD (with *r*^2^ = 1) were associated with reduced odds of insufficiency (Table [4](#Tab4){ref-type="table"}).Table 4Genotype association with vitamin D~3~ status at baselineGeneSNPs IDOR (95 % CI)*p* value*GC*rs2220140.476 (0.27--0.84)0.009*CYP24A1*rs4809958^a^0.570 (0.35--0.92)0.021*CYP24A1*rs6013905^a^0.580 (0.36--0.93)0.021*GC*rs4588^b,c^1.65 (1.07--2.58)0.026*GC*rs2282679^b^1.65 (1.07--2.58)0.02625(OH)D~3~ reference group is sufficient (coded as zero), 1 = deficient + insufficient; increase in odds of deficient/insufficient for each additional copy of variant allele^a^SNPs in linkage disequilibrium \[LD\] with each other^b^SNPs in linkage disequilibrium \[LD\] with each other^c^This SNP is located in an exon, all others are in introns

Discussion {#Sec14}
==========

In this study, 64.9 % of CRC patients had baseline serum 25(OH)D~3~ levels less than 32 ng/mL. Similar high percentage of vitamin D~3~ deficient and insufficient individuals have been reported in healthy controls and patients with acute myeloid leukemia, colorectal, prostate, and breast cancer in Western New York \[[@CR24]--[@CR26]\]. Therefore, the high prevalence of vitamin D~3~ deficiency in these CRC patients simply reflects the vitamin D~3~ status of the general population in Western New York. As expected, 25(OH)D~3~ levels were higher in blood samples collected in summer/fall than in samples collected in winter/spring. There was no association between 25(OH)D~3~ levels and race perhaps because of the small sample size of Black Americans in this study.

The increase in 25(OH)D~3~ and decrease in PTH levels which we observed in all vitamin D~3~ status categories, is consistent with prior reports and were expected as physiologic response to D~3~ supplementation. However, other reports indicate that D~3~ supplementation has no effect on serum PTH levels \[[@CR27], [@CR28]\]. These contradictory observations may reflect differences in D~3~ supplementation doses utilized, calcium homeostasis related to dietary calcium intake and other calciotropic hormones. Our data suggest that serum 24,25(OH)~2~D~3~, 1,25(OH)~2~D~3~, and VDBP levels are of limited value as measures of response to D~3~ supplementation. Changes in serum 25(OH)D~3~ without associated change in serum 1,25(OH)~2~D~3~ levels during D~3~ supplements has been reported \[[@CR29]\]. Moreover, there is no difference in baseline serum 24,25(OH)~2~D~3~ levels in these CRC patients (1.4 ± 0.5 ng/mL) and that reported in healthy controls \[[@CR30], [@CR31]\]. This finding suggests that 25(OH)D~3~-24-hydroxylation may not play a critical role in the pathogenesis of systemic vitamin D~3~ insufficiency in CRC patients. The use of serum 24,25(OH)~2~D~3~ levels in evaluating the role of 24-hydroxylase in vitamin D~3~ status and responses to cholecalciferol supplementation is, however, of limited value because of its further metabolism, by the same enzyme, to 25(OH)D~3~-23,26-lactone and cholecalcoic acid. Whereas, the decrease in 25(OH)D~3~ is not a useful measure of 24-hydroxylase because it is also a substrate of non 24-hydroxylase enzymes such as CYP11A1 \[[@CR32], [@CR33]\].

We found two major kinetic differences between the changes in total and free serum 25(OH)D~3~, 24,25(OH)~2~D~3~, and 1,25(OH)~2~D~3~ levels during D~3~ supplementation: First, while the increase in total serum 25(OH)D~3~ and 24,25(OH)~2~D~3~ levels was biphasic, the increase in total serum 1,25(OH)~2~D~3~ levels was linear. Second, free indices of both 25(OH)D~3~ and 24,25(OH)~2~D~3~ increased whereas 1,25(OH)~2~D~3~ free index did not change. These observations suggest that changes in total and free serum 1,25(OH)~2~D~3~ levels were insufficient to trigger changes in PBMC 24-OHase and serum calcium levels. Free 1,25(OH)~2~D~3~ index is the serum measure highly correlated with hypercalcemia \[[@CR34]\]. Although underlying mechanisms of the kinetic differences in 25(OH)D~3~ and 1,25(OH)~2~D~3~ changes during D~3~ supplementation are unknown, we suggest tight reciprocal regulation of 1,25(OH)~2~D~3~ levels by CYP24A1 and CYP27B1 catalyzed metabolism prevents the increase serum 1,25(OH)~2~D~3~ levels. Differences in the VDBP capacity and binding affinity along with variations in adipose tissue storage may play a further role in regulating serum 1,25(OH)~2~D~3~ levels. The percentages of free forms of 25(OH)D~3~ and 1,25(OH)~2~D~3~ in circulation are 0.04 % and 0.4 %, respectively while VDBP affinity for 25(OH)D~3~ is 5 × 10^−8^--9.5 × 10^−11^ M compared to ∼4 × 10^−7^ M for 1,25(OH)~2~D~3~ \[[@CR35], [@CR36]\].

Our results show that genetic variants of *GC* SNPs rs4588 and rs2282679 were associated with low baseline levels of 25(OH)D~3~ and 1,25(OH)~2~D~3~, with increased odds of vitamin D~3~ insufficiency and with suboptimal response to D~3~ supplementation in CRC patients. These findings are consistent with previous reports where these same SNPs have been associated with low serum 25(OH)D~3~ in both healthy and patients with a variety of diseases including cancer \[[@CR7]--[@CR11]\] and reduced serum 25(OH)D~3~ changes after vitamin D~3~ supplementation in healthy volunteers \[[@CR12]\]. Although, genome wide studies have associated *CYP2R1* SNPs rs10500804 and rs12794714, with vitamin D levels and vitamin D insufficiency \[[@CR7], [@CR8]\] the present study only showed an association after supplementation.

*GC* SNP rs222014 and *CYP24A1* SNPs rs4809958 and rs6013905 were associated with reduced risk of vitamin D~3~ insufficiency, while *GC* SNPs rs4588 and rs2282679 were associated with increased risk of insufficiency. However, it is unclear why *GC* rs222016 and *CYP24A1* rs111675277, SNPs associated with high 25(OH)D~3~ levels, were not associated with reduced risk of D~3~ insufficiency. Possible explanations may include differences in statistical analysis (continuous vs. categorical OR), the character of the colorectal cancer disease itself and/or small sample size. Thus *GC* rs222014 and *CYP24A1* rs4809958 and rs6013905 SNPs could be potential predictive markers for low risk vitamin D~3~ insufficiency, while *GC* rs4588 and rs2282679 may be both predictive of insufficiency and reduced response to D~3~ supplementation in CRC patients.

In summary, we found that baseline serum 25(OH)D~3~ levels and polymorphisms in the vitamin D~3~ pathway genes, especially in the *GC* and *CYP24A1* genes affect response to D~3~ supplementation in CRC patients and are associated with increased risk of vitamin D~3~ insufficiency. Further studies, in large populations, are needed to confirm and determine if individuals with *GC* rs4588 or rs2282679 SNPs require higher doses of D~3~ supplementation to achieve vitamin D~3~ sufficiency.
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